AIDS Vaccine Advocacy Coalition Voices Disappointment in Tr...(that the candidate did notprotect agains...),Health

Date:9/21/2007

that the candidate did not protect against infection. The STEP Study enrolled its first participant in December 2004, and we have a definitive answer less than three years later. Getting swift, precise answers about candidates is crucial for the field. In this sense, the STEP Study fulfilled its purpose-as disappointing as the results may be.

One reason for this efficiency is that both STEP and its companion trial Phambili, which tested the candidate in South Africa, were designed as "test- of-concept" trials, to give an initial answer about vaccine benefits in a relatively abbreviated timeframe. The STEP Study met its enrollment targets and its endpoint goals within the timeframe specified by the trial planners.

About AVAC

Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a non- profit, community- and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other HIV prevention options. To help assure its independence, AVAC does not accept funding from government or pharmaceutical industry sources. For more information, visit http://www.avac.org.

'/>"/>

SOURCE AIDS Vaccine Advocacy Coalition Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
6. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus